Exact Sciences Corporation: Business Overview, Financials & Competitive Analysis
Exact Sciences Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Market-leading precision oncology diagnostics company with strong cash generation and growth trajectory, though acquisition by Abbott pending completion resolves long-term strategic direction. The company raised full-year 2025 revenue guidance to between $3.22 billion and $3.235 billion, with screening revenue hitting $666 million in Q3 2025 alone. The non-GAAP gross.
What is Exact Sciences Corporation's industry? Exact Sciences Corporation (exactsciences.com) operates in Molecular Diagnostics & Precision Oncology. AskCyborg classifies Exact Sciences Corporation under Molecular Diagnostics & Precision Oncology in its company registry.
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company is best known for developing Cologuard, a non-invasive, stool-based DNA screening...
Cyborg Score thesis
Market-leading precision oncology diagnostics company with strong cash generation and growth trajectory, though acquisition by...
Read the full analyst-debate transcript →Get the Latest Exact Sciences Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeExact Sciences Corporation Overview
Pro stress-test →Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company is best known for developing Cologuard, a non-invasive, stool-based DNA screening test for colorectal cancer that has transformed cancer screening accessibility. The company is currently undergoing acquisition by Abbott Laboratories.
Strategic Profile
Pro stress-test →The company has expanded its portfolio to include Oncotype DX, a suite of genomic tests that analyze tumor biology to guide treatment decisions, and through strategic acquisitions and internal development, has positioned itself as a leader in precision oncology, offering comprehensive cancer screening, diagnosis, and treatment selection solutions. In November 2025, Abbott Laboratories agreed to acquire Exact Sciences in a deal worth roughly $21 billion.
Competitive Landscape
Pro stress-test →Exact Sciences stands alongside industry leaders like Illumina and Laboratory Corporation with significant revenue and employee base, indicating a competitive environment where offerings like automation, diagnostics, and personalized medicine solutions are crucial for capturing additional market share in cancer detection and research support. Other competitors include Guardant Health, Natera, Veracyte, and Personalis in the molecular diagnostics space.
Industry Context
Exact Sciences Corporation operates in Molecular Diagnostics & Precision Oncology.
Key facts
Founded: 1995 · Headquarters: Madison, Wisconsin · Employees: 6,900 · Revenue: $3.2B · Market cap: $19.7B